San Francisco, CA, December 18, 2017 – 5AM Venture Management LLC (“5AM”) of San Francisco, CA and Boston, MA is pleased to announce the addition of Amy Burroughs as an Executive-In-Residence.

“We are delighted to announce that Amy is joining our team of investment professionals,” said Andy Schwab, Managing Partner. “Amy’s extensive life science background and impressive array of leadership roles will add significant value to both 5AM and our portfolio companies.”

Ms. Burroughs has over twenty years of experience as a leader in healthcare and life sciences. She began her biotechnology career at Genentech in 2001 where her roles included commercial strategy and commercial leadership in neurology. She was the Chief Commercial Officer and Head of Business Development for APT Pharmaceuticals and has served as an advisor to many privately funded life sciences companies since 2010. Beginning in 2012, Ms. Burroughs spent three years with Egon Zehnder as an advisor on leadership development, talent and board governance. Early in her career, Ms. Burroughs worked in brand management at Procter & Gamble and headed marketing for several venture funded healthcare services and technology companies. Ms. Burroughs holds a computer science and economics degree from Dartmouth and an MBA from Harvard University where she graduated as a Baker Scholar.

About 5AM Ventures
Founded in 2002, 5AM actively invests in next-generation life science companies. With ~$1 billion under management, 5AM has invested in 65 companies and successful exits which include Audentes Therapeutics (Nasdaq: BOLD), Cidara Therapeutics (Nasdaq: CDTX), DVS Sciences (acquired by Fluidigm), Envoy Therapeutics (acquired by Takeda), Flexion Therapeutics (Nasdaq: FLXN), Ikaria (acquired by Mallinckrodt), Ilypsa (acquired by Amgen), Incline Therapeutics (acquired by The Medicines Company), Marcadia Biotech (acquired by Roche), Novira Therapeutics (acquired by J&J), Pearl Therapeutics (acquired by AstraZeneca), Relypsa (Nasdaq: RLYP, acquired by Galenica), and scPharmaceuticals (Nasdaq: SCPH).